US20030215422A1
(en)
|
1996-09-11 |
2003-11-20 |
John A. Chiorini |
Aav4 vector and uses thereof
|
AU762220B2
(en)
|
1998-05-28 |
2003-06-19 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
AAV5 vector and uses thereof
|
US20030027135A1
(en)
|
2001-03-02 |
2003-02-06 |
Ecker David J. |
Method for rapid detection and identification of bioagents
|
US7666588B2
(en)
|
2001-03-02 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
|
US7718354B2
(en)
|
2001-03-02 |
2010-05-18 |
Ibis Biosciences, Inc. |
Methods for rapid identification of pathogens in humans and animals
|
US20040121309A1
(en)
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
|
US7226739B2
(en)
|
2001-03-02 |
2007-06-05 |
Isis Pharmaceuticals, Inc |
Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
|
US7217510B2
(en)
|
2001-06-26 |
2007-05-15 |
Isis Pharmaceuticals, Inc. |
Methods for providing bacterial bioagent characterizing information
|
US8073627B2
(en)
|
2001-06-26 |
2011-12-06 |
Ibis Biosciences, Inc. |
System for indentification of pathogens
|
BRPI0214119B8
(pt)
|
2001-11-13 |
2021-05-25 |
Univ Pennsylvania |
vírus adenoassociado recombinante, método de geração do referido vírus e composição compreendendo o referido vírus
|
EP2573170B1
(en)
*
|
2001-12-17 |
2017-12-20 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor
|
PT1453547T
(pt)
|
2001-12-17 |
2016-12-28 |
Univ Pennsylvania |
Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
|
WO2003093460A1
(en)
|
2002-04-29 |
2003-11-13 |
The Trustees Of The University Of Pennsylvania |
Method for direct rescue and amplification of integrated viruses from cellular dna of tissues
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
AU2003265855A1
(en)
*
|
2002-08-28 |
2004-03-19 |
University Of Florida |
Modified aav
|
JP2006516193A
(ja)
|
2002-12-06 |
2006-06-29 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ヒトおよび動物における病原体の迅速な同定方法
|
US8046171B2
(en)
|
2003-04-18 |
2011-10-25 |
Ibis Biosciences, Inc. |
Methods and apparatus for genetic evaluation
|
US8057993B2
(en)
|
2003-04-26 |
2011-11-15 |
Ibis Biosciences, Inc. |
Methods for identification of coronaviruses
|
US7964343B2
(en)
|
2003-05-13 |
2011-06-21 |
Ibis Biosciences, Inc. |
Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
US8158354B2
(en)
|
2003-05-13 |
2012-04-17 |
Ibis Biosciences, Inc. |
Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
WO2005017101A2
(en)
|
2003-05-19 |
2005-02-24 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH |
Avian adenoassociated virus (aaav) and uses thereof
|
DK2657248T3
(da)
|
2003-06-19 |
2017-06-26 |
Genzyme Corp |
AAV-virions med reduceret immunreaktivitet og anvendelser deraf
|
US9233131B2
(en)
*
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
NZ545656A
(en)
*
|
2003-09-01 |
2009-02-28 |
Amc Amsterdam |
AAV vectors for in vivo gene therapy of rheumatoid arthritis
|
AU2010201278B2
(en)
*
|
2003-09-01 |
2012-11-15 |
Academisch Medisch Centrum |
AAV vectors for in vivo gene therapy of rheumatoid arthritis
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US8394945B2
(en)
|
2003-09-11 |
2013-03-12 |
Ibis Biosciences, Inc. |
Compositions for use in identification of bacteria
|
US8546082B2
(en)
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
PT3211085T
(pt)
|
2003-09-30 |
2021-06-17 |
Univ Pennsylvania |
Clados de vírus adeno-associados (aav), sequências, vetores que as contêm, e suas utilizações
|
AU2011250849B2
(en)
*
|
2003-09-30 |
2013-09-12 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
|
WO2005056807A2
(en)
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
US8163895B2
(en)
|
2003-12-05 |
2012-04-24 |
Ibis Biosciences, Inc. |
Compositions for use in identification of orthopoxviruses
|
US7666592B2
(en)
|
2004-02-18 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for concurrent identification and quantification of an unknown bioagent
|
US8119336B2
(en)
|
2004-03-03 |
2012-02-21 |
Ibis Biosciences, Inc. |
Compositions for use in identification of alphaviruses
|
WO2006033672A2
(en)
|
2004-04-28 |
2006-03-30 |
The Trustees Of The University Of Pennsylvania |
Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
|
CA2563538C
(en)
*
|
2004-04-28 |
2013-12-17 |
The Trustees Of The University Of Pennsylvania |
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
|
CA2567839C
(en)
|
2004-05-24 |
2011-06-28 |
Isis Pharmaceuticals, Inc. |
Mass spectrometry with selective ion filtration by digital thresholding
|
US20050266411A1
(en)
|
2004-05-25 |
2005-12-01 |
Hofstadler Steven A |
Methods for rapid forensic analysis of mitochondrial DNA
|
US7811753B2
(en)
|
2004-07-14 |
2010-10-12 |
Ibis Biosciences, Inc. |
Methods for repairing degraded DNA
|
WO2006073496A2
(en)
*
|
2004-07-30 |
2006-07-13 |
Targeted Genetics Corporation |
Recombinant aav based vaccine methods
|
US7309589B2
(en)
*
|
2004-08-20 |
2007-12-18 |
Vironix Llc |
Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
|
MX2007003922A
(es)
*
|
2004-10-05 |
2007-06-07 |
Merz Pharma Gmbh & Co Kgaa |
Nuevas propenonas ciclicas y aciclicas para tratar trastornos del sistema nervioso central.
|
US8084207B2
(en)
|
2005-03-03 |
2011-12-27 |
Ibis Bioscience, Inc. |
Compositions for use in identification of papillomavirus
|
CA2600184A1
(en)
|
2005-03-03 |
2006-09-08 |
Isis Pharmaceuticals, Inc. |
Compositions for use in identification of adventitious viruses
|
CN101203613B
(zh)
*
|
2005-04-07 |
2012-12-12 |
宾夕法尼亚大学托管会 |
增强腺相关病毒载体功能的方法
|
WO2006119432A2
(en)
*
|
2005-04-29 |
2006-11-09 |
The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services |
Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
|
CA2616281C
(en)
|
2005-07-21 |
2014-04-22 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification and quantitation of mitochondrial dna variants
|
EP1957678B1
(en)
*
|
2005-11-28 |
2012-06-13 |
Ibis Biosciences, Inc. |
Compositions for use in identification of adventitious contaminant viruses
|
EP2007795B1
(en)
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid proteins
|
CN101528916B
(zh)
|
2006-04-28 |
2013-09-04 |
宾夕法尼亚大学托管会 |
规模可调的aav生产方法
|
ES2398593T3
(es)
*
|
2006-07-25 |
2013-03-20 |
Celladon Corporation |
Infusión coronaria epicárdica anterógrada prolongada de vectores víricos adeno-asociados que comprenden SERCA2a para la terapia génica
|
EP2064332B1
(en)
|
2006-09-14 |
2012-07-18 |
Ibis Biosciences, Inc. |
Targeted whole genome amplification method for identification of pathogens
|
WO2008104002A2
(en)
|
2007-02-23 |
2008-08-28 |
Ibis Biosciences, Inc. |
Methods for rapid forensic dna analysis
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
LT2191001T
(lt)
|
2007-04-09 |
2016-10-10 |
University Of Florida Research Foundation, Inc. |
Raav vektoriaus kompozicijos, turinčios tirozin-modifikuotų kapsidės baltymų ir jų panaudojimo būdai
|
US9611302B2
(en)
|
2007-04-09 |
2017-04-04 |
University Of Florida Research Foundation, Inc. |
High-transduction-efficiency RAAV vectors, compositions, and methods of use
|
US9598724B2
(en)
|
2007-06-01 |
2017-03-21 |
Ibis Biosciences, Inc. |
Methods and compositions for multiple displacement amplification of nucleic acids
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
ES2538468T3
(es)
|
2008-05-20 |
2015-06-22 |
Eos Neuroscience, Inc. |
Vectores para la administración de proteínas sensibles a la luz y métodos para su utilización
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US8550694B2
(en)
|
2008-09-16 |
2013-10-08 |
Ibis Biosciences, Inc. |
Mixing cartridges, mixing stations, and related kits, systems, and methods
|
WO2010033625A1
(en)
|
2008-09-16 |
2010-03-25 |
Ibis Biosciences, Inc. |
Microplate handling systems and related computer program products and methods
|
US8148163B2
(en)
|
2008-09-16 |
2012-04-03 |
Ibis Biosciences, Inc. |
Sample processing units, systems, and related methods
|
WO2010093943A1
(en)
|
2009-02-12 |
2010-08-19 |
Ibis Biosciences, Inc. |
Ionization probe assemblies
|
PL2425000T3
(pl)
|
2009-04-30 |
2019-08-30 |
The Trustees Of The University Of Pennsylvania |
Kompozycje do kierowania komórek przewodzących do dróg oddechowych zawierające konstrukty wirusów związanych z adenowirusami
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
WO2010143761A1
(ko)
*
|
2009-06-12 |
2010-12-16 |
(주)바이오니아 |
미지시료 내 감염성 미생물을 신속하게 검출하는 방법
|
EP2454000A4
(en)
|
2009-07-17 |
2016-08-10 |
Ibis Biosciences Inc |
SYSTEMS FOR IDENTIFYING BIOLOGICAL SUBSTANCES
|
US8950604B2
(en)
|
2009-07-17 |
2015-02-10 |
Ibis Biosciences, Inc. |
Lift and mount apparatus
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
EP2488656B1
(en)
|
2009-10-15 |
2015-06-03 |
Ibis Biosciences, Inc. |
Multiple displacement amplification
|
CN102869779A
(zh)
|
2010-03-29 |
2013-01-09 |
宾夕法尼亚大学托管会 |
药理学诱导的转基因消融系统
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
EP3444346B1
(en)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
WO2011133890A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
US9309534B2
(en)
|
2010-07-12 |
2016-04-12 |
Universidad Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
EP2699688A1
(en)
|
2011-04-20 |
2014-02-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
SG194583A1
(en)
|
2011-04-22 |
2013-12-30 |
Univ California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
US9169299B2
(en)
*
|
2011-08-24 |
2015-10-27 |
The Board Of Trustees Of The Leleand Stanford Junior University |
AAV capsid proteins for nucleic acid transfer
|
US20130136729A1
(en)
*
|
2011-11-11 |
2013-05-30 |
University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group |
Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
|
CN104520428B
(zh)
*
|
2012-02-17 |
2018-09-21 |
费城儿童医院 |
将基因转移到细胞、器官和组织的aav载体组合物和方法
|
WO2013130393A1
(en)
*
|
2012-02-28 |
2013-09-06 |
Cornell University |
Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
|
WO2013154744A1
(en)
*
|
2012-04-13 |
2013-10-17 |
Cornell University |
Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
ES2741502T3
(es)
|
2013-02-08 |
2020-02-11 |
Univ Pennsylvania |
Cápside de AAV8 modificada para la transferencia génica para terapias de retina
|
DK2956477T4
(da)
|
2013-02-15 |
2024-04-15 |
Bioverativ Therapeutics Inc |
Optimeret faktor viii-gen
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
ES2805355T3
(es)
|
2013-03-15 |
2021-02-11 |
Univ Pennsylvania |
Composiciones para tratar MPSI
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
JP6600624B2
(ja)
|
2013-05-31 |
2019-10-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノ随伴ウイルス変異体及びその使用方法
|
WO2015013313A2
(en)
|
2013-07-22 |
2015-01-29 |
The Children's Hospital Of Philadelphia |
Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
|
SI3099333T1
(sl)
|
2014-01-31 |
2021-04-30 |
Temple University of the Commonwealth System of Higher Education 1938 Liacouras Walk |
BAG3 kot tarča za terapijo srčne odpovedi
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
SI3116900T1
(sl)
|
2014-03-09 |
2021-02-26 |
The Trustees Of The University Of Pennsylvania |
Sestavki uporabni pri zdravljenju pomanjkanja ornitin transkarbamilaze(OTC)
|
CN106414474B
(zh)
|
2014-03-17 |
2021-01-15 |
阿德夫拉姆生物技术股份有限公司 |
用于视锥细胞中增强的基因表达的组合物和方法
|
WO2015143078A1
(en)
|
2014-03-18 |
2015-09-24 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
HUE046454T2
(hu)
|
2014-03-21 |
2020-03-30 |
Genzyme Corp |
Retinitis pigmentosa génterápia
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
EP3134115A4
(en)
|
2014-04-25 |
2017-10-25 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
WO2015164778A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennysylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
SG11201609207SA
(en)
|
2014-05-13 |
2016-12-29 |
Univ Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
AU2015283850B2
(en)
|
2014-07-03 |
2020-06-04 |
Board Of Regents, University Of Texas System |
GLS1 inhibitors for treating disease
|
EP4012035A1
(en)
|
2014-09-16 |
2022-06-15 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
CA2961523A1
(en)
|
2014-09-16 |
2016-03-24 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
CN112553229A
(zh)
|
2014-11-05 |
2021-03-26 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
DK3218386T3
(da)
|
2014-11-14 |
2021-06-07 |
Voyager Therapeutics Inc |
Modulatorisk polynukleotid
|
KR102599909B1
(ko)
|
2014-11-14 |
2023-11-09 |
보이저 테라퓨틱스, 인크. |
근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
CA2974235A1
(en)
|
2015-01-07 |
2016-07-14 |
Universitat Autonoma De Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
US20180021364A1
(en)
|
2015-01-16 |
2018-01-25 |
Voyager Therapeutics, Inc. |
Central nervous system targeting polynucleotides
|
CA2974378A1
(en)
|
2015-01-20 |
2016-07-28 |
Genzyme Corporation |
Analytical ultracentrifugation for characterization of recombinant viral particles
|
WO2016126857A1
(en)
*
|
2015-02-03 |
2016-08-11 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
PT3256594T
(pt)
|
2015-02-10 |
2022-01-18 |
Genzyme Corp |
Entrega intensificada de partículas virais ao corpo estriado e córtex
|
WO2016130589A2
(en)
|
2015-02-10 |
2016-08-18 |
Genzyme Corporation |
VARIANT RNAi
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
WO2016141078A1
(en)
|
2015-03-02 |
2016-09-09 |
Avalanche Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
US20180042991A1
(en)
|
2015-03-10 |
2018-02-15 |
The Trustees Of Columbia University In The City Of New York |
Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
アデノ随伴ウイルス変異体及びその使用方法
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
EP3285788A4
(en)
|
2015-04-23 |
2018-12-05 |
University of Massachusetts |
Modulation of aav vector transgene expression
|
WO2016172008A1
(en)
|
2015-04-24 |
2016-10-27 |
University Of Massachusetts |
Modified aav constructions and uses thereof
|
US20180110877A1
(en)
|
2015-04-27 |
2018-04-26 |
The Trustees Of The University Of Pennsylvania |
DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
CA2985081A1
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-influenza antibodies and methods of use thereof
|
RU2021132397A
(ru)
|
2015-05-16 |
2022-02-24 |
Джензим Корпорейшн |
Генное редактирование глубоких интронных мутаций
|
MX2018000307A
(es)
|
2015-06-23 |
2018-05-02 |
Childrens Hospital Philadelphia |
Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
|
US10676735B2
(en)
|
2015-07-22 |
2020-06-09 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
KR20180038558A
(ko)
|
2015-08-25 |
2018-04-16 |
듀크 유니버시티 |
Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법
|
KR20180057636A
(ko)
|
2015-08-31 |
2018-05-30 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
반려 동물 치료용 aav-epo
|
KR20180055872A
(ko)
|
2015-09-24 |
2018-05-25 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
보체 매개 질환 치료용 조성물 및 방법
|
EP3831842A1
(en)
|
2015-09-28 |
2021-06-09 |
The University of North Carolina at Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
JP2019501115A
(ja)
|
2015-10-28 |
2019-01-17 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
遺伝子治療のためのアデノ随伴ウイルスベクターのくも膜下腔内投与
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
CA3001941A1
(en)
|
2015-10-30 |
2017-05-04 |
Nbe-Therapeutics Ag |
Anti-ror1 antibodies
|
EP3384035A4
(en)
|
2015-12-02 |
2019-08-07 |
Voyager Therapeutics, Inc. |
ASSAYS FOR DETECTION OF NEUTRALIZING ANTIBODIES OF VAA
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
EP3387138B1
(en)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
BR112018011687A2
(pt)
|
2015-12-11 |
2018-12-04 |
Univ Pennsylvania |
terapia de gene para tratar hipercolesterolemia familiar
|
WO2017100676A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
AU2016370487C1
(en)
|
2015-12-14 |
2022-03-03 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
CA3007330A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of crigler-najjar syndrome
|
KR20180098294A
(ko)
|
2015-12-15 |
2018-09-03 |
젠자임 코포레이션 |
뮤코지질증 ii형을 치료하기 위한 아데노-관련 바이러스 벡터
|
BR112018014615A2
(pt)
|
2016-01-20 |
2018-12-11 |
The Scripps Research Institute |
composições de anticorpo para ror1 e métodos relacionados
|
US11753461B2
(en)
|
2016-02-01 |
2023-09-12 |
Bioverativ Therapeutics Inc. |
Optimized factor VIII genes
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
US10973929B2
(en)
|
2016-02-03 |
2021-04-13 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type I
|
EP4094780A3
(en)
|
2016-02-12 |
2023-02-08 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
WO2017151717A1
(en)
*
|
2016-03-01 |
2017-09-08 |
French Brent A |
Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
IL298604A
(en)
|
2016-04-15 |
2023-01-01 |
Univ Pennsylvania |
Novel aav8 mutant capsids and preparations containing them
|
AU2017248731A1
(en)
|
2016-04-15 |
2018-10-18 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
SG10201912761UA
(en)
|
2016-04-15 |
2020-02-27 |
The Trustees Of The Univ Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
US11191847B2
(en)
|
2016-04-15 |
2021-12-07 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating hemophilia B
|
SG11201808422QA
(en)
|
2016-04-15 |
2018-10-30 |
Univ Pennsylvania |
Gene therapy for treating hemophilia a
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
GB201608046D0
(en)
*
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
ES2941502T3
(es)
|
2016-05-13 |
2023-05-23 |
4D Molecular Therapeutics Inc |
Variantes de cápsides de virus adenoasociado y procedimientos de utilización de las mismas
|
AU2017267665C1
(en)
|
2016-05-18 |
2023-10-05 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
CA3024449A1
(en)
|
2016-05-18 |
2017-11-23 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
US11158076B2
(en)
|
2016-06-08 |
2021-10-26 |
Sony Corporation |
Imaging control device and method, and vehicle
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
CA3029864A1
(en)
|
2016-07-05 |
2018-01-11 |
University Of Massachusetts |
Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
|
AU2017292010B2
(en)
|
2016-07-08 |
2023-07-27 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving RDH12
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
JP6994018B2
(ja)
|
2016-07-26 |
2022-01-14 |
バイオマリン ファーマシューティカル インコーポレイテッド |
新規アデノ随伴ウイルスキャプシドタンパク質
|
JP7071332B2
(ja)
|
2016-07-29 |
2022-05-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
変異カプシドを有するアデノ随伴ウイルスビリオン及びその使用方法
|
MX2019001938A
(es)
|
2016-08-15 |
2019-07-04 |
Genzyme Corp |
Metodos para detectar aav.
|
AU2017321488B2
(en)
|
2016-08-30 |
2022-10-20 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
EP3518985A4
(en)
*
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
US11578340B2
(en)
|
2016-10-13 |
2023-02-14 |
University Of Massachusetts |
AAV capsid designs
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
WO2018100054A1
(en)
|
2016-12-01 |
2018-06-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
US11584931B2
(en)
|
2016-12-14 |
2023-02-21 |
The J. David Gladstone Institutes |
Methods and compositions for generating a deletion library and for identifying a defective interfering particle (DIP)
|
US11382941B2
(en)
*
|
2016-12-30 |
2022-07-12 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating Phenylketonuria
|
EP3571298A4
(en)
|
2017-01-20 |
2020-10-21 |
University of Pittsburgh - of The Commonwealth System of Higher Education |
TREATMENT FOR CRAB'S LATERAL CORD BLOOD TRANSPLANTATION (UCBT) AND INCREASED GALACTOCEREBROSIDASE (GALC) EXPRESSION
|
US11554147B2
(en)
|
2017-02-20 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
SG10201913833PA
(en)
|
2017-02-28 |
2020-03-30 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
CA3053399A1
(en)
|
2017-02-28 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) clade f vector and uses therefor
|
CA3054136A1
(en)
|
2017-03-01 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
EP3589311A1
(en)
|
2017-03-02 |
2020-01-08 |
Genethon |
Method for removing anti-aav antibodies from a blood-derived composition
|
EP3606544A4
(en)
|
2017-04-05 |
2021-04-07 |
University of Massachusetts |
MINI-GENE THERAPY
|
EP3610016A1
(en)
|
2017-04-10 |
2020-02-19 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
KR20190139951A
(ko)
|
2017-04-14 |
2019-12-18 |
리젠엑스바이오 인크. |
인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
|
US11879133B2
(en)
|
2017-04-24 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
AU2018261003A1
(en)
|
2017-05-05 |
2019-11-14 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's Disease
|
US11603542B2
(en)
|
2017-05-05 |
2023-03-14 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
CA3059213A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
SG11201910015SA
(en)
|
2017-05-11 |
2019-11-28 |
Univ Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinoses
|
JP2020519294A
(ja)
|
2017-05-12 |
2020-07-02 |
ユニバーシティ オブ マサチューセッツ |
ウイルスベクター産生
|
CN108103058A
(zh)
*
|
2017-05-12 |
2018-06-01 |
北京五加和分子医学研究所有限公司 |
一种i型糖尿病的基因治疗药物
|
CA3098592A1
(en)
|
2017-05-31 |
2018-12-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
JP2020522269A
(ja)
|
2017-06-06 |
2020-07-30 |
ユニバーシティ オブ マサチューセッツ |
レット症候群におけるmecp2の安全な発現のための自己調節aavベクター
|
JP2020527335A
(ja)
|
2017-06-14 |
2020-09-10 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
眼疾患のための遺伝子療法
|
US10721272B2
(en)
|
2017-06-15 |
2020-07-21 |
Palo Alto Networks, Inc. |
Mobile equipment identity and/or IOT equipment identity and application identity based security enforcement in service provider networks
|
US10693918B2
(en)
|
2017-06-15 |
2020-06-23 |
Palo Alto Networks, Inc. |
Radio access technology based security in service provider networks
|
US10708306B2
(en)
|
2017-06-15 |
2020-07-07 |
Palo Alto Networks, Inc. |
Mobile user identity and/or SIM-based IoT identity and application identity based security enforcement in service provider networks
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
US10812532B2
(en)
|
2017-06-15 |
2020-10-20 |
Palo Alto Networks, Inc. |
Security for cellular internet of things in mobile networks
|
US11050789B2
(en)
|
2017-06-15 |
2021-06-29 |
Palo Alto Networks, Inc. |
Location based security in service provider networks
|
JP2020525010A
(ja)
*
|
2017-06-22 |
2020-08-27 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
制御性免疫細胞を産生するための方法及びその使用
|
US11890329B2
(en)
|
2017-07-06 |
2024-02-06 |
The Trustees Of The University Of Pennsylvania |
AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
|
CA3069045A1
(en)
|
2017-07-07 |
2019-01-10 |
Genethon |
Novel polynucleotides encoding a human fkrp protein
|
AU2018302016A1
(en)
|
2017-07-17 |
2020-02-06 |
The Regents Of The University Of California |
Trajectory array guide system
|
CA3071978A1
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
SG11202000846WA
(en)
|
2017-08-07 |
2020-02-27 |
Nbe Therapeutics Ag |
Anthracycline-based antibody drug conjugates having high in vivo tolerability
|
CN110709511A
(zh)
*
|
2017-08-28 |
2020-01-17 |
加利福尼亚大学董事会 |
腺相关病毒衣壳变体及其使用方法
|
SG11202002276VA
(en)
|
2017-09-20 |
2020-04-29 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and methods of use thereof
|
BR112020005569A2
(pt)
|
2017-09-22 |
2020-10-06 |
Genzyme Corporation |
rna de interferência (rnai) variante
|
SG11202002457RA
(en)
|
2017-09-22 |
2020-04-29 |
Univ Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
CA3075643A1
(en)
|
2017-09-22 |
2019-03-28 |
University Of Massachusetts |
Sod1 dual expression vectors and uses thereof
|
EP3692151A4
(en)
*
|
2017-10-03 |
2021-07-14 |
Prevail Therapeutics, Inc. |
GENE THERAPIES FOR LYSOSOMAL DISORDERS
|
TWI804518B
(zh)
|
2017-10-16 |
2023-06-11 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
CA3079565A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
|
RU2020112558A
(ru)
|
2017-10-18 |
2021-11-18 |
Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем |
Терапия на основе ингибитора глутаминазы
|
BR112020007405A2
(pt)
|
2017-10-18 |
2020-12-08 |
Regenxbio Inc. |
Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
|
EP4272728A2
(en)
|
2017-11-27 |
2023-11-08 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
US11723989B2
(en)
|
2017-11-30 |
2023-08-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis IIIB
|
AU2018375164A1
(en)
|
2017-11-30 |
2020-06-04 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for Mucopolysaccharidosis IIIA
|
JP2021506861A
(ja)
|
2017-12-19 |
2021-02-22 |
アコーオス インコーポレイテッド |
内耳への治療用抗体のaav媒介送達
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
F8遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
EP3762500A1
(en)
|
2018-03-06 |
2021-01-13 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
JP2021519065A
(ja)
|
2018-03-23 |
2021-08-10 |
ユニバーシティ オブ マサチューセッツ |
骨障害を処置するための遺伝子治療法
|
JP7406677B2
(ja)
|
2018-04-03 |
2023-12-28 |
ギンコ バイオワークス インコーポレイテッド |
抗体を回避するウイルスベクター
|
CA3098448A1
(en)
|
2018-04-27 |
2019-10-31 |
University Of Massachusetts |
Aav capsids identified by in vivo library selection
|
WO2019212921A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Scalable clarification process for recombinant aav production
|
EP3788165A1
(en)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
WO2019217582A1
(en)
|
2018-05-08 |
2019-11-14 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
US11739345B2
(en)
|
2018-05-09 |
2023-08-29 |
Biomarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
CA3099306A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
US20210230632A1
(en)
|
2018-05-15 |
2021-07-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
WO2019222441A1
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
EP3793615A2
(en)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Directed evolution of aav to improve tropism for cns
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
EP3807404A1
(en)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
JP7385603B2
(ja)
|
2018-06-14 |
2023-11-22 |
リジェネクスバイオ インコーポレイテッド |
組換えaav生成のためのアニオン交換クロマトグラフィー
|
CN112567035A
(zh)
|
2018-07-02 |
2021-03-26 |
沃雅戈治疗公司 |
肌萎缩侧索硬化症及脊髓相关病症的治疗
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
MX2021000810A
(es)
|
2018-07-24 |
2021-04-28 |
Voyager Therapeutics Inc |
Sistemas y metodos para producir formulaciones de terapia genetica.
|
US20210292790A1
(en)
*
|
2018-07-30 |
2021-09-23 |
Gene Therapy Research Institution Co., Ltd. |
Method for enhancing gene expression using aav vector
|
KR20210062627A
(ko)
|
2018-08-03 |
2021-05-31 |
젠자임 코포레이션 |
알파-시뉴클레인에 대한 변이형 RNAi
|
KR20210043580A
(ko)
|
2018-08-10 |
2021-04-21 |
리젠엑스바이오 인크. |
재조합 aav 생산을 위한 규모 조정 가능한 방법
|
JP7450945B2
(ja)
|
2018-08-30 |
2024-03-18 |
テナヤ セラピューティクス, インコーポレイテッド |
ミオカルディンおよびascl1を用いた心細胞リプログラミング
|
US20210403923A1
(en)
|
2018-09-28 |
2021-12-30 |
President And Fellows Of Harvard College |
Mutant reverse tetracycline transactivators for expression of genes
|
WO2020069373A1
(en)
|
2018-09-28 |
2020-04-02 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
US20210395776A1
(en)
|
2018-09-28 |
2021-12-23 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
AU2019351815A1
(en)
|
2018-10-01 |
2021-05-06 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating GM1 gangliosidosis
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
SG11202103425YA
(en)
|
2018-10-05 |
2021-05-28 |
Voyager Therapeutics Inc |
Engineered nucleic acid constructs encoding aav production proteins
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
JP2022504740A
(ja)
|
2018-10-12 |
2022-01-13 |
ジェンザイム・コーポレーション |
肝臓に向けられた遺伝子補充療法によって重度のpkuを処置するための改善されたヒトpahの生成
|
WO2020081490A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
KR20210075994A
(ko)
|
2018-10-15 |
2021-06-23 |
리젠엑스바이오 인크. |
복제 결함 바이러스 벡터 및 바이러스의 감염성을 측정하는 방법
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
JP2022513376A
(ja)
|
2018-10-22 |
2022-02-07 |
ユニバーシティ オブ ロチェスター |
レトロウイルスインテグラーゼ-Cas9融合タンパク質を使用した指向性非相同DNA挿入によるゲノム編集
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
EP3650956A1
(fr)
|
2018-11-07 |
2020-05-13 |
Tissot S.A. |
Procede de diffusion d'un signal acoustique
|
MX2021005720A
(es)
|
2018-11-16 |
2021-07-21 |
Astellas Pharma Inc |
Metodo para tratar la distrofia muscular mediante el direccionamiento del gen de utrofina.
|
US20220054656A1
(en)
*
|
2018-11-16 |
2022-02-24 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus for treating pompe disease
|
US20220033824A1
(en)
|
2018-11-29 |
2022-02-03 |
University Of Massachusetts |
Modulation of sptlc1 via recombinant adeno-associated vectors
|
US20220089670A1
(en)
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
SG11202106855YA
(en)
|
2019-01-04 |
2021-07-29 |
Ultragenyx Pharmaceutical Inc |
Gene therapy constructs for treating wilson disease
|
JP7416451B2
(ja)
|
2019-01-14 |
2024-01-17 |
ユニバーシティ オブ ロチェスター |
CRISPR-Casによる標的化された核内RNA切断及びポリアデニル化
|
JP2022522995A
(ja)
|
2019-01-18 |
2022-04-21 |
ボイジャー セラピューティクス インコーポレイテッド |
Aav粒子を生成するための方法及びシステム
|
EP3917566A4
(en)
|
2019-01-31 |
2022-10-26 |
Oregon Health & Science University |
METHODS OF USING DIRECTED, TRANSCRIPTION-DEPENDENT EVOLUTION OF AAV CAPSIDS
|
CA3131023A1
(en)
|
2019-02-22 |
2020-08-27 |
Michael R. Volkert |
Oxr1 gene therapy
|
JP2022523766A
(ja)
|
2019-02-22 |
2022-04-26 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Grn関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
|
BR112021016501A2
(pt)
|
2019-02-25 |
2021-10-26 |
Novartis Ag |
Composições e métodos para tratar distrofia cristalina de bietti
|
EP3931335A2
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Compositions and methods to treat bietti crystalline dystrophy
|
AU2020229772A1
(en)
|
2019-02-26 |
2021-08-26 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
CA3131919A1
(en)
|
2019-02-28 |
2020-09-03 |
Regeneron Pharmaceuticals, Inc. |
Adeno-associated virus vectors for the delivery of therapeutics
|
JP2022526526A
(ja)
|
2019-03-25 |
2022-05-25 |
ジェネトン |
オーバーラップaavベクターを使用する大きいサイズのクアシジストロフィンの産生
|
KR20220004987A
(ko)
|
2019-04-03 |
2022-01-12 |
리젠엑스바이오 인크. |
눈 병리에 대한 유전자 요법
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
PL3953483T3
(pl)
|
2019-04-11 |
2024-04-22 |
Regenxbio Inc. |
Sposoby chromatografii wykluczania do charakteryzowania kompozycji rekombinowanych wirusów towarzyszących adenowirusom
|
WO2020215010A1
(en)
|
2019-04-17 |
2020-10-22 |
Codiak Biosciences, Inc. |
Compositions of exosomes and aav
|
WO2020214929A1
(en)
|
2019-04-19 |
2020-10-22 |
Regenxbio Inc. |
Adeno-associated virus vector formulations and methods
|
AU2020262416A1
(en)
|
2019-04-24 |
2021-12-16 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
KR20220004695A
(ko)
*
|
2019-04-29 |
2022-01-11 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
신규 aav 캡시드 및 이를 포함하는 조성물
|
TW202106879A
(zh)
|
2019-04-29 |
2021-02-16 |
美商航海家醫療公司 |
於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
JP2022533438A
(ja)
*
|
2019-05-24 |
2022-07-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
改変ウイルス粒子およびその使用
|
SG11202111427RA
(en)
|
2019-05-28 |
2021-11-29 |
Astellas Pharma Inc |
Method for treating muscular dystrophy by targeting dmpk gene
|
EP3987024A4
(en)
|
2019-06-20 |
2023-11-01 |
University Of Massachusetts |
COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING
|
AU2020298575A1
(en)
|
2019-07-02 |
2022-02-24 |
M6P Therapeutics (Switzerland) GmbH |
Vector compositions and methods of using same for treatment of lysosomal storage disorders
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
WO2021007515A1
(en)
|
2019-07-11 |
2021-01-14 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
CN114729331A
(zh)
|
2019-07-11 |
2022-07-08 |
法国国家科学研究中心 |
化学修饰的腺相关病毒
|
US10557149B1
(en)
*
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
US10653731B1
(en)
*
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
US20220267773A1
(en)
|
2019-07-23 |
2022-08-25 |
University Of Rochester |
Targeted RNA cleavage with CRISPR-Cas
|
JP2022544004A
(ja)
|
2019-07-26 |
2022-10-17 |
リジェネックスバイオ インコーポレイテッド |
操作された核酸調節エレメントならびにその使用方法
|
WO2021021674A1
(en)
|
2019-07-26 |
2021-02-04 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
US20220290182A1
(en)
|
2019-08-09 |
2022-09-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
JP2022546236A
(ja)
*
|
2019-08-14 |
2022-11-04 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. |
遺伝子治療のためのaavカプシドバリアント
|
BR112022003811A2
(pt)
|
2019-08-26 |
2022-11-16 |
Regenxbio Inc |
Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
CA3152288A1
(en)
|
2019-08-27 |
2021-03-04 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of disorders associated with repetitive dna
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
US20220340643A1
(en)
|
2019-09-13 |
2022-10-27 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
WO2021053124A1
(en)
|
2019-09-19 |
2021-03-25 |
Genethon |
Gene therapy expression system alleviating cardiac toxicity of fkrp
|
US11834659B2
(en)
|
2019-09-26 |
2023-12-05 |
Massachusetts Institute Of Technology |
Trans-activated functional RNA by strand displacement and uses thereof
|
US11492622B2
(en)
|
2019-09-26 |
2022-11-08 |
Massachusetts Institute Of Technology |
MicroRNA-based logic gates and uses thereof
|
US20220347298A1
(en)
|
2019-10-04 |
2022-11-03 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
CA3156984A1
(en)
|
2019-10-07 |
2021-04-15 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
US20230121437A1
(en)
|
2019-10-15 |
2023-04-20 |
University Of Massachusetts |
Rna editor-enhanced rna trans-splicing
|
EP4045664A1
(en)
*
|
2019-10-16 |
2022-08-24 |
Wuxi Apptec (Shanghai) Co., Ltd. |
A novel aav variant
|
MX2022004352A
(es)
|
2019-10-17 |
2022-07-19 |
Stridebio Inc |
Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c.
|
CN114829391A
(zh)
|
2019-11-14 |
2022-07-29 |
生物马林药物股份有限公司 |
用肝特异性基因疗法载体治疗遗传性血管性水肿
|
EP4061943A1
(en)
|
2019-11-19 |
2022-09-28 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antisense oligonucleotides and their use for the treatment of cancer
|
US20230270886A1
(en)
|
2019-11-28 |
2023-08-31 |
Regenxbio Inc. |
Microdystrophin gene therapy constructs and uses thereof
|
IL293684A
(en)
|
2019-12-10 |
2022-08-01 |
Takeda Pharmaceuticals Co |
Adeno-related virus vectors for the treatment of Hunter disease
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
AU2021211416A1
(en)
|
2020-01-22 |
2022-08-11 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis I with fully-human glycosylated human alpha-L-iduronidase (IDUA)
|
JP2023512242A
(ja)
|
2020-01-29 |
2023-03-24 |
レジェンクスバイオ インコーポレーテッド |
ヒト神経細胞またはヒトグリア細胞が産生した組換えヒトイズロン酸-2-スルファターゼ(ids)によるムコ多糖症iiの治療
|
TW202136516A
(zh)
|
2020-01-29 |
2021-10-01 |
美商銳進科斯生物股份有限公司 |
Iva型黏多醣病之治療
|
EP4096707A1
(en)
|
2020-01-30 |
2022-12-07 |
Umoja Biopharma, Inc. |
Bispecific transduction enhancer
|
KR20220145838A
(ko)
|
2020-02-02 |
2022-10-31 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Gm1 강글리오사이드증을 치료하는 데 유용한 조성물
|
JP2023514149A
(ja)
|
2020-02-07 |
2023-04-05 |
ユニバーシティ オブ ロチェスター |
リボザイムにより媒介されるrnaアセンブリ及び発現
|
JP2023513211A
(ja)
|
2020-02-07 |
2023-03-30 |
ユニバーシティ オブ ロチェスター |
タンパク質合成を増強するためのCRISPR-Cas13による標的RNA翻訳
|
AU2021218703A1
(en)
|
2020-02-14 |
2022-07-28 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating CDKL5 deficiency disorder
|
BR112022017551A2
(pt)
|
2020-03-02 |
2022-11-16 |
Tenaya Therapeutics Inc |
Controle de vetor genético por micrornas expressos por cardiomiócito
|
EP4127169A1
(en)
|
2020-03-27 |
2023-02-08 |
University of Rochester |
Targeted destruction of viral rna by crispr-cas13
|
WO2021195525A1
(en)
|
2020-03-27 |
2021-09-30 |
University Of Rochester |
Crispr-cas13 crrna arrays
|
WO2021191424A1
(en)
|
2020-03-27 |
2021-09-30 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
KR20230113689A
(ko)
|
2020-03-31 |
2023-08-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 변이체 및 그의 용도
|
EP4127189A1
(en)
|
2020-03-31 |
2023-02-08 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
AR122409A1
(es)
|
2020-04-03 |
2022-09-07 |
Biomarin Pharm Inc |
Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
|
JP2023520927A
(ja)
|
2020-04-10 |
2023-05-22 |
ソラ・バイオサイエンシズ・エルエルシー |
タンパク質凝集障害の処置のための組成物および方法
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
CN115836129A
(zh)
|
2020-04-28 |
2023-03-21 |
索拉生物科学有限公司 |
用于治疗tdp-43蛋白病的组合物和方法
|
CA3177924A1
(en)
|
2020-05-12 |
2021-11-18 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
CA3177407A1
(en)
|
2020-05-12 |
2021-11-18 |
James M. Wilson |
Compositions for drg-specific reduction of transgene expression
|
BR112022022906A2
(pt)
|
2020-05-13 |
2023-01-17 |
Akouos Inc |
Composições e métodos para tratar perda auditiva associada a slc26a4
|
WO2021231538A2
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
CA3183251A1
(en)
|
2020-06-05 |
2021-12-09 |
Sola Biosciences Llc |
Compositions and methods for the treatment of synucleinopathies
|
KR20230025000A
(ko)
|
2020-06-17 |
2023-02-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
유전자 요법 환자의 치료를 위한 조성물 및 방법
|
WO2021255245A2
(en)
|
2020-06-19 |
2021-12-23 |
Genethon |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
CN116194587A
(zh)
|
2020-07-10 |
2023-05-30 |
吉尼松公司 |
一种新的肌肉特异性启动子
|
JP2023540429A
(ja)
|
2020-07-10 |
2023-09-25 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
てんかんを治療するための方法及び組成物
|
US20230270884A1
(en)
|
2020-07-13 |
2023-08-31 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treatment of charcot-marie-tooth disease
|
US20230348871A1
(en)
|
2020-07-15 |
2023-11-02 |
University Of Rochester |
Targeted RNA cleavage with dCas13-RNase Fusion Proteins
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
CN117120619A
(zh)
|
2020-07-27 |
2023-11-24 |
沃雅戈治疗公司 |
用于治疗与葡萄糖神经酰胺酶β缺陷相关的神经病症的组合物和方法
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
CN116209430A
(zh)
|
2020-08-07 |
2023-06-02 |
阿米库斯治疗学公司 |
囊泡靶向蛋白及其用途
|
AU2021320902A1
(en)
|
2020-08-07 |
2023-04-06 |
Spacecraft Seven, Llc |
Plakophilin-2 (PKP2) gene therapy using AAV vector
|
CN114075610B
(zh)
*
|
2020-08-11 |
2023-11-17 |
北京荷塘生华医疗科技有限公司 |
检测野生型腺相关病毒的通用引物及其应用
|
KR20230051208A
(ko)
|
2020-08-14 |
2023-04-17 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
신규 aav 캡시드 및 이를 함유하는 조성물
|
GB202013194D0
(en)
|
2020-08-24 |
2020-10-07 |
Combigene Ab |
Gene therapy for lipodystrophy
|
AU2021332235A1
(en)
|
2020-08-24 |
2023-03-23 |
The Trustees Of The University Of Pennsylvania |
Viral vectors encoding GLP-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
EP4204014A1
(en)
|
2020-08-26 |
2023-07-05 |
The Trustees of The University of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
WO2022056000A1
(en)
|
2020-09-09 |
2022-03-17 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of duchenne muscular dystrophy
|
CN116323641A
(zh)
|
2020-09-10 |
2023-06-23 |
路德维希-马克西米利安慕尼黑大学 |
工程化的aav载体
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
WO2022061002A1
(en)
|
2020-09-18 |
2022-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
US11401531B2
(en)
|
2020-09-24 |
2022-08-02 |
University Of Massachusetts |
AAV vectors encoding NF1 and uses thereof
|
CA3193866A1
(en)
|
2020-10-01 |
2022-04-07 |
Sirkka R.M. Kyostio-Moore |
Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
AU2021358781A1
(en)
|
2020-10-07 |
2023-05-18 |
Regenxbio Inc. |
Gene therapy for ocular manifestations of cln2 disease
|
WO2022076591A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
CA3193697A1
(en)
|
2020-10-07 |
2022-04-14 |
Joseph Bruder |
Adeno-associated viruses for ocular delivery of gene therapy
|
KR20230106598A
(ko)
|
2020-10-07 |
2023-07-13 |
리젠엑스바이오 인크. |
겔 제형과 같은 맥락막위 투여용 제형
|
US20240024508A1
(en)
|
2020-10-07 |
2024-01-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
EP4225906A1
(en)
|
2020-10-09 |
2023-08-16 |
The Trustees of The University of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
AU2021359874A1
(en)
|
2020-10-18 |
2023-05-25 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
US20230391864A1
(en)
|
2020-10-28 |
2023-12-07 |
Regenxbio, Inc. |
Vectorized anti-tnf-alpha antibodies for ocular indications
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
WO2022094255A2
(en)
|
2020-10-29 |
2022-05-05 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
CA3196964A1
(en)
|
2020-10-29 |
2022-05-05 |
Xu Wang |
Vectorized tnf-alpha antagonists for ocular indications
|
US20230414648A1
(en)
|
2020-11-06 |
2023-12-28 |
Vertex Pharmaceuticals Incorporated |
Compositions and Methods for Treatment of DM1 with SLUCAS9 and SACAS9
|
CN112322791B
(zh)
*
|
2020-11-27 |
2023-10-27 |
福建省农业科学院畜牧兽医研究所 |
一种新型鸭依赖属病毒环介导等温扩增检测引物组及试剂盒
|
JP2023551533A
(ja)
|
2020-12-01 |
2023-12-08 |
アコーオス インコーポレイテッド |
前庭神経鞘腫関連症状を治療するための抗vegf抗体構築物及び関連する方法
|
JP2023551903A
(ja)
|
2020-12-01 |
2023-12-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組織特異的標的化モチーフを有する新規組成物及びそれを含有する組成物
|
CA3200192A1
(en)
|
2020-12-01 |
2022-06-09 |
Justin PERCIVAL |
Compositions and uses thereof for treatment of angelman syndrome
|
IL303614A
(en)
|
2020-12-16 |
2023-08-01 |
Regenxbio Inc |
A method for producing an ADNO-linked recombinant virus particle
|
WO2022147087A1
(en)
|
2020-12-29 |
2022-07-07 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
EP4271419A1
(en)
|
2020-12-29 |
2023-11-08 |
Akouos, Inc. |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
|
US20240084329A1
(en)
|
2021-01-21 |
2024-03-14 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
WO2022164935A1
(en)
|
2021-01-27 |
2022-08-04 |
Umoja Biopharma, Inc. |
Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
|
AU2022214429A1
(en)
|
2021-02-01 |
2023-09-14 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
KR20230145386A
(ko)
|
2021-02-10 |
2023-10-17 |
리젠엑스바이오 인크. |
재조합 인간 이두로네이트-2-설파타아제(ids)를 사용한 점액다당류증 ii의 치료
|
GB202101958D0
(en)
|
2021-02-12 |
2021-03-31 |
Ucl Business Ltd |
Gene therapy for dopamine transporter deficiency syndrome
|
TW202302848A
(zh)
|
2021-02-26 |
2023-01-16 |
美商維泰克斯製藥公司 |
以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法
|
WO2022182959A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
IL305440A
(en)
|
2021-02-26 |
2023-10-01 |
Takeda Pharmaceuticals Co |
Preparation and methods for treating Fabry disease
|
TW202246516A
(zh)
|
2021-03-03 |
2022-12-01 |
美商航海家醫療公司 |
病毒蛋白之控制表現
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
CN117460832A
(zh)
|
2021-03-22 |
2024-01-26 |
建新公司 |
空aav衣壳和完整aav衣壳的尺寸排阻色谱分析
|
WO2022204476A1
(en)
|
2021-03-26 |
2022-09-29 |
The Board Of Regents Of The University Of Texas System |
Nucleotide editing to reframe dmd transcripts by base editing and prime editing
|
CA3215141A1
(en)
|
2021-04-12 |
2022-10-20 |
James M. Wilson |
Compositions useful for treating spinal and bulbar muscular atrophy (sbma)
|
AR125406A1
(es)
|
2021-04-23 |
2023-07-12 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
|
AU2022261125A1
(en)
|
2021-04-23 |
2023-11-23 |
University Of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
BR112023021999A2
(pt)
|
2021-04-26 |
2023-12-26 |
Regenxbio Inc |
Administração de terapia gênica de microdistrofina para tratamento de distrofinopatias
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
EP4334454A2
(en)
|
2021-05-04 |
2024-03-13 |
RegenxBio Inc. |
Novel aav vectors and methods and uses thereof
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
EP4337267A1
(en)
|
2021-05-11 |
2024-03-20 |
RegenxBio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
CA3223292A1
(en)
|
2021-06-25 |
2022-12-29 |
Laura Van Lieshout |
Adeno-associated virus packaging systems
|
EP4363437A1
(en)
|
2021-07-01 |
2024-05-08 |
Amicus Therapeutics, Inc. |
Neurotensin variants and tagged proteins comprising neurotensin or sortilin propeptide
|
CA3225985A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
AR126407A1
(es)
|
2021-07-08 |
2023-10-11 |
Tenaya Therapeutics Inc |
Casetes de expresión optimizada para genoterapia
|
WO2023004331A1
(en)
|
2021-07-19 |
2023-01-26 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
CA3233097A1
(en)
|
2021-09-30 |
2023-04-06 |
Katherine Diane GRIBBLE |
Compositions and methods for treating kcnq4-associated hearing loss
|
TW202332472A
(zh)
|
2021-10-01 |
2023-08-16 |
美商拜奧馬林製藥公司 |
利用aav基因療法載體進行之遺傳性血管水腫治療及治療性調配物
|
TW202325845A
(zh)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
新穎aav衣殼及含其之組成物
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060248A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
AU2022371442A1
(en)
|
2021-10-21 |
2024-04-18 |
Vertex Pharmaceuticals Incorporated |
Hypoimmune cells
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
WO2023102442A1
(en)
|
2021-11-30 |
2023-06-08 |
Jaguar Gene Therapy, Llc |
Gene therapy methods for treatment of diabetes
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
WO2023111348A1
(en)
|
2021-12-17 |
2023-06-22 |
Centre National De La Recherche Scientifique |
Peptides and methods for use in treating pain
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023133593A2
(en)
*
|
2022-01-10 |
2023-07-13 |
University Of Florida Research Foundation, Incorporated |
Aav5 capsid variants
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
AR128239A1
(es)
|
2022-01-10 |
2024-04-10 |
Univ Pennsylvania |
Composiciones y métodos útiles para el tratamiento de trastornos mediados por c9orf72
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023150142A1
(en)
|
2022-02-02 |
2023-08-10 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
WO2023154693A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023156530A1
(en)
|
2022-02-17 |
2023-08-24 |
Lysogene |
Gene therapy for neurodegenerative diseases
|
TW202345911A
(zh)
|
2022-03-08 |
2023-12-01 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
|
WO2023172926A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
TW202346590A
(zh)
|
2022-03-13 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
經修飾之肌肉特異性啟動子
|
WO2023178220A1
(en)
|
2022-03-16 |
2023-09-21 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2023196862A1
(en)
|
2022-04-06 |
2023-10-12 |
Genzyme Corporation |
Targeted gene therapy for dm-1 myotonic dystrophy
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
WO2023198652A1
(en)
|
2022-04-11 |
2023-10-19 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
US20230346977A1
(en)
|
2022-04-13 |
2023-11-02 |
Universitat Autònoma De Barcelona |
Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
TW202405173A
(zh)
|
2022-04-18 |
2024-02-01 |
美商維泰克斯製藥公司 |
用於增強aav療法及降低aav向肝臟之趨性的組合物及方法
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023227731A1
(en)
|
2022-05-25 |
2023-11-30 |
Tafalgie Therapeutics |
Peptides and methods for use in treating pain
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
WO2024006770A1
(en)
*
|
2022-06-27 |
2024-01-04 |
Astellas Gene Therapies, Inc. |
Compositions and methods for the treatment of myotonic dystrophies
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
CN115354049A
(zh)
*
|
2022-07-29 |
2022-11-18 |
中国科学院深圳先进技术研究院 |
一种基因递送系统在将目的基因经静脉注射递送至肝脏的应用
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
CN116622908B
(zh)
*
|
2023-04-13 |
2024-02-06 |
武汉珈创生物技术股份有限公司 |
快速检测野生型腺相关病毒的引物探针、试剂盒及方法和应用
|